Compare FLGT & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLGT | UROY |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.3M | 601.8M |
| IPO Year | 2016 | N/A |
| Metric | FLGT | UROY |
|---|---|---|
| Price | $15.77 | $4.22 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.33 | N/A |
| AVG Volume (30 Days) | 516.5K | ★ 2.2M |
| Earning Date | 05-01-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,730,000.00 | N/A |
| Revenue This Year | $10.09 | $279.20 |
| Revenue Next Year | $12.18 | N/A |
| P/E Ratio | ★ N/A | $1,584.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.46 | $1.81 |
| 52 Week High | $31.04 | $5.52 |
| Indicator | FLGT | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 61.03 |
| Support Level | $15.39 | $3.54 |
| Resistance Level | $16.70 | $4.58 |
| Average True Range (ATR) | 0.69 | 0.24 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 70.33 | 73.54 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.